Welcome to our dedicated page for Oramed Pharmaceuticals SEC filings (Ticker: ORMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oramed Pharmaceuticals Inc. reports material events and financial information through SEC filings that document its oral drug delivery business, investment-related agreements, and capital actions. Recent 8-K disclosures cover operating and financial results, option and warrant-related arrangements, payments tied to strategic investments, cash dividends, and material definitive agreements involving company assets and subsidiaries.
The filings also document Oramed’s common stock registration on the Nasdaq Capital Market and Tel Aviv Stock Exchange, its shareholder rights agreement, board-authorized distributions, and other capital-structure and governance matters. These records connect the company’s clinical-stage POD technology platform and oral insulin program with formal disclosures on liquidity, securities, contractual rights, and corporate events.
Oramed Pharmaceuticals Chief Financial Officer Avraham Gabay received an equity grant of 95,889 Restricted Stock Units (RSUs). The RSUs vest in eight equal quarterly installments beginning on April 1, 2026, encouraging longer-term retention. Each RSU converts into one share of common stock when it vests, bringing his direct holdings to 745,145 shares after the award.
ORAMED PHARMACEUTICALS INC. President and CEO Nadav Kidron reported a bona fide charitable gift of 100,000 shares of Common Stock on March 12, 2026. The filing states this was a charitable donation, not a market transaction, and no value was received for the shares.
Following the donation, Kidron directly holds 3,255,238 shares of Oramed common stock. The footnote further explains that he is not affiliated with, and has no control over, the charitable donee, underscoring that this is a non-economic transfer rather than a sale in the open market.
Oramed Pharmaceuticals Inc. entered into a new warrant agreement with Scilex Holding Company on February 19, 2026. In return for previously deferring an amortization payment on Scilex’s senior secured convertible Tranche B Notes, Oramed received a February 2026 warrant to purchase 100,000 shares of Scilex common stock at an initial exercise price of $20.00 per share.
The warrant is immediately exercisable and expires on December 13, 2029. Its exercise price is adjustable for stock splits and certain future offerings, but not below a floor price of $8.22. The warrant includes a beneficial ownership cap of 4.99%, which Oramed may raise up to 9.99% with 61 days’ notice. It also contains protections in change-of-control and other fundamental transactions, including a right for Oramed to require cash repurchase of the unexercised portion at its Black Scholes value.
BML Investment Partners, L.P. and Braden M. Leonard filed an amended Schedule 13G disclosing a significant stake in Oramed Pharmaceuticals Inc. Leonard reports beneficial ownership of 3,287,531 shares of common stock, representing 8.3% of the class, including 120,300 shares over which he has sole voting and dispositive power and 3,167,231 shares with shared power.
The filing states these securities are not held for the purpose of changing or influencing control of Oramed, and the reporting persons disclaim that they form a statutory group.
Oramed Pharmaceuticals executive Joshua Hexter reported a share-based award vesting. On January 22, 2026, 19,000 performance stock units vested after Oramed’s common stock reached a specified price target. Each unit converted into one common share, giving Hexter 19,000 shares received for no cash consideration.
Following this conversion, Hexter directly holds 1,064,495 shares of Oramed common stock. The performance stock units were granted on December 31, 2025, and no derivative units of this grant remain outstanding after the vesting.
Oramed Pharmaceuticals (ORMP) director and Chief Scientific Officer Miriam Kidron reported the vesting of performance stock units (PSUs) into common shares. On January 22, 2026, 19,000 PSUs vested after Oramed’s common stock reached a specified price level.
Each PSU converted into one share of common stock, so Kidron received 19,000 shares of Oramed common stock for no cash consideration. Following this equity-based award, she directly beneficially owns 1,448,664 shares of Oramed common stock, reflecting her ongoing equity stake in the company.
Oramed Pharmaceuticals Inc. Chief Financial Officer Avraham Gabay reported the vesting of 19,000 performance stock units into common shares. The PSUs were granted on December 31, 2025 and vested on January 22, 2026 after Oramed’s common stock reached a specified price per share.
Each PSU converted into one share of common stock, and the shares were received for no cash consideration. Following this transaction, Gabay directly beneficially owns 649,256 shares of Oramed common stock.
Oramed Pharmaceuticals Inc. insider filing: President and CEO Nadav Kidron reported the vesting of performance stock units tied to Oramed’s share price. On January 22, 2026, 109,000 PSUs converted into 109,000 shares of common stock for no cash consideration.
Each PSU gave the right to receive one share when specific performance criteria were met. Following this vesting, Kidron directly owns 3,355,238 shares of Oramed common stock.
Oramed Pharmaceuticals director and Chief Scientific Officer Miriam Kidron reported a charitable donation of company stock. On 01/14/2026, she gifted 86,166 shares of Oramed Pharmaceuticals Inc. common stock in a transaction coded "G," which is designated for gifts. The filing states this was a charitable donation, not a market trade, so no price was reported and no value was received for the shares.
After the donation, Kidron beneficially owned 1,343,498 shares of Oramed common stock in direct ownership form. The footnote adds that she is not affiliated with, and has no control over, the recipient organization.
Oramed Pharmaceuticals signed a major deal with Lifeward Ltd. to sell all of its Oratech Pharma subsidiary. In return, Oramed will receive Lifeward ordinary shares, very low-priced pre-funded warrants, and additional warrants that together could give it up to 49.99% of Lifeward’s fully diluted equity, subject to ownership limits and shareholder approval. Oramed will also receive 4% of net revenue from Lifeward’s ReWalk Personal Exoskeleton products until a time or value cap is reached or Lifeward’s market value hits $200 million.
Separately, Oramed agreed to buy $9,000,000 of senior secured convertible notes from Lifeward now, with an option for another $9,000,000 later if performance or share price targets are met. These notes and related warrants are convertible into Lifeward shares at an initial price of $0.45 per share, with anti-dilution adjustments and caps to keep Oramed’s ownership initially below 45.0%. Oramed also committed to a 120‑day lock-up on Lifeward securities it receives and will manage Oratech’s oral insulin clinical study under a reimbursed services agreement.